ABIVAX |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.58 EUR | +2.78% |
|
+0.16% | +28.11% |
| May. 20 | BTIG Initiates Abivax at Buy Rating With $43 Price Target | MT |
| May. 08 | Abivax: four abstracts to be presented on obefazimod | CF |
| Sales 2024 * | 3.51M 3.81M | Sales 2025 * | 2.51M 2.72M | Capitalization | 792M 858M |
|---|---|---|---|---|---|
| Net income 2024 * | -161M -175M | Net income 2025 * | -174M -189M | EV / Sales 2024 * | 201 x |
| Net cash position 2024 * | 87.4M 94.78M | Net cash position 2025 * | 44.68M 48.45M | EV / Sales 2025 * | 298 x |
| P/E ratio 2024 * |
-4.56
x | P/E ratio 2025 * |
-4.45
x | Employees | 61 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.17% |
More Fundamentals
* Assessed data
More news
Latest transcript on Abivax
More recommendations
More press releases
More news
| 1 day | +2.78% | ||
| 1 week | +0.16% | ||
| 1 month | -14.77% | ||
| 3 months | -0.63% | ||
| 6 months | +37.34% | ||
| Current year | +28.11% |
1 week
12.04
12.94
1 month
12.0414.40
Current year
9.3515.42
1 year
7.8919.18
3 years
5.6036.70
5 years
5.6039.00
10 years
3.8739.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 66 | 23-05-04 | |
Didier Blondel
DFI | Director of Finance/CFO | - | 17-01-01 |
Sheldon Sloan
CTO | Chief Tech/Sci/R&D Officer | - | 23-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 65 | 13-12-03 | |
Kinam Hong
BRD | Director/Board Member | - | - |
Troy Ignelzi
BRD | Director/Board Member | 56 | 23-07-10 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 12.58 | +2.78% | 42,730 |
| 24-05-30 | 12.24 | -1.13% | 15,861 |
| 24-05-29 | 12.38 | -3.28% | 15,874 |
| 24-05-28 | 12.8 | +0.31% | 13,787 |
| 24-05-27 | 12.76 | +1.59% | 5,519 |
Real-time Euronext Paris, May 31, 2024 at 11:35 am EDT
More quotes
Abivax develops innovative treatments modulating the body's natural immune system machinery to treat patients with chronic inflammatory diseases, viral infections and cancer.
As a clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis, Crohn's disease, rheumatoid arthritis, and other inflammatory diseases (ABX464) as well as liver cancer (ABX196). The Company's mission is to utilize its drug development platforms to bring innovative and effective solutions to patients in these therapeutic areas with significant unmet needs.
Calendar
2024-09-08
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
12.58
EUR
Average target price
37.56
EUR
Spread / Average Target
+198.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +28.11% | 858M | |
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +0.04% | 12.16B | |
| +25.12% | 12.21B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- ABVX Stock
